Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer Lett. 2013 Mar 21;334(2):228–236. doi: 10.1016/j.canlet.2013.03.011

Figure 4. Efficacy of p53-gene therapy by surface-modified NPs in prostate tumors.

Figure 4

Tumor-bearing mice were treated with two doses of unmodified p53NPs, CTAB-p53NPs, and DMAB-p53NPs, with each dose equivalent to 60 μg of p53 plasmid DNA. Controls included saline and DMAB-CNPs made with control plasmid. Tumor volume was monitored over time (a). Tumor volume is shown up to the time point when most animals were still alive. The area under the curve (calculated 0 through day 17, the day the first animal died) demonstrated significantly greater reduction in overall tumor growth in the DMAB-p53NP group vs. all other treated and control groups (*p< 0.05) (b). This Kaplan-Meier plot shows improvement in animal survival after treatment with DMAB-p53NPs vs. other treatment and control groups. Log-rank test of DMAB-p53NP and each group yields *p ≤ 0.05 (c).